- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02274181
An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration
March 11, 2015 updated by: Repros Therapeutics Inc.
The purpose of this study is to investigate the route(s) of elimination and mass balance of enclomiphene after oral administration of a single 25 mg (approximately equivalent to [(~]) 500 nanocurie [nCi]) dose of [14C]Androxal in healthy adult male subjects.
Study Overview
Detailed Description
The purpose of this study is to investigate the route(s) of elimination and mass balance of enclomiphene after oral administration of a single 25 mg (approximately equivalent to [(~]) 500 nanocurie [nCi]) dose of [14C]Androxal in healthy adult male subjects.
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- Celerion
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years to 58 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy, adult, male subjects, 19 60 years of age, inclusive, at screening
- Continuous non smoker who has not used nicotine containing products for at least 3 months prior to dosing
- Body mass index (BMI) ≥ 25.0 and ≤ 42.0 kg/m2 at screening
- Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI
- A non vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study drug. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to study start. A male who has been vasectomized less than 4 months prior to study start must follow the same restrictions as a non vasectomized male)
- Must agree not to donate sperm from dosing until 90 days after dosing
- Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol
Exclusion Criteria:
- Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study
- History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI
- History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subject by their participation in the study
- History or presence of alcoholism or drug abuse within the past 2 years prior to screening
- History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds (e.g., clomiphene citrate)
History or presence of:
- Renal disease or a history of renal dysfunction;
- Liver disease or a history of liver dysfunction;
- Uncontrolled thyroid or adrenal dysfunction or in the presence of an organic intracranial lesion such as a pituitary tumor;
- Previous history of deep vein thrombosis, pulmonary embolism or a high risk for stroke
- Conditions which are known to be exacerbated by testosterone replacement or are driven by androgen sensitivity
- Regularly have less than 1 bowel movement every 2 days
- Recent history (within 2 weeks of Day -1) of abnormal bowel habits, such as diarrhea, loose stools, or constipation
- Positive urine drug or alcohol results at screening or check in
- Positive urine cotinine at screening
- Positive results at screening for HIV, HBsAg or HCV
- Poor metabolizer for CYP2D6 based on genotyping for CYP2D6 at screening (since CYP2D6 is key enzyme for enclomiphene drug metabolism).2
Unable to refrain from or anticipates the use of:
- Any drug, including prescription and non prescription medications (including any drugs known to be significant inhibitors of CYP enzymes and/or P gp and/or OATP), herbal remedies, or vitamin supplements beginning 14 days prior to dosing of study drug and throughout the study. Acetaminophen (up to 2 g per 24 hour period) and Milk of Magnesia (≤ 60 mL per day) may be permitted during the study
- Any drugs known to be significant inducers of CYP enzymes and/or P gp, including St. John's Wort, for 28 days prior to dosing of study drug and throughout the study. Appropriate sources will be consulted by the PI or designee to confirm lack of PK/pharmacodynamics (PD) interaction with study drug
- Have been on a diet incompatible with the on study diet, in the opinion of the PI, within the 28 days prior to dosing of study drug, and throughout the study
- Have received radiolabeled substances or have been exposed to radiation sources over the past 12 months or is likely to receive radiation exposure or radioisotopes within the next 12 months such that participation in this study would increase their total exposure beyond the recommended levels considered safe (i.e., weighted annual limit recommended by the ICRP of 3000 mrem)
- Donation of blood or significant blood loss within 56 days prior to dosing of study drug
- Plasma donation within 7 days prior to dosing of study drug
- Participation in another clinical trial within 28 days prior to dosing of study drug. The 28 day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of the current study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 25 mg (approximately equivalent to [(~]) 500 nanocurie
A single 25 mg (approximately equivalent to [(~]) 500 nanocurie [nCi]) dose of [14C]Androxal
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Androxal excreted via the urine, feces and blood
Time Frame: 8 Days
|
Determined by AMS lab by analysis of all excreted samples
|
8 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2014
Primary Completion (Actual)
January 1, 2015
Study Completion (Actual)
January 1, 2015
Study Registration Dates
First Submitted
October 6, 2014
First Submitted That Met QC Criteria
October 22, 2014
First Posted (Estimate)
October 24, 2014
Study Record Updates
Last Update Posted (Estimate)
March 12, 2015
Last Update Submitted That Met QC Criteria
March 11, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Gonadal Disorders
- Hypogonadism
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Estrogen Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Enclomiphene
Other Study ID Numbers
- ZA-112
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Secondary Hypogonadism
-
Clarus Therapeutics, Inc.CompletedMale Hypogonadism | Secondary Hypogonadism | Primary HypogonadismUnited States
-
Endo PharmaceuticalsCompletedHypogonadism | Secondary Hypogonadism | Primary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedSecondary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedSecondary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedSecondary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedSecondary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedSecondary HypogonadismUnited States
-
Repros Therapeutics Inc.Completed
-
Repros Therapeutics Inc.CompletedSecondary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedSecondary HypogonadismUnited States
Clinical Trials on Androxal
-
Repros Therapeutics Inc.Completed
-
Repros Therapeutics Inc.Completed
-
Repros Therapeutics Inc.CompletedSecondary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedPharmacokineticsUnited States
-
Repros Therapeutics Inc.Completed
-
Repros Therapeutics Inc.CompletedDrug-drug InteractionUnited States
-
Repros Therapeutics Inc.CompletedType 2 Diabetes Mellitus | Secondary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedSecondary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedSecondary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedEffect of Treatment on Bone Mineral DensityUnited States